News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited to Move to Phase 2 Trial of NNZ-2566 on TBI
September 20, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sydney, Sep 20, 2007 -- Neuren Pharmaceuticals has completed cohorts 1 and 2 of its Phase 1b trial to test the safety, tolerability and pharmacokinetic action of NNZ-2566 as a compound to treat traumatic brain injury (TBI).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Australia
MORE ON THIS TOPIC
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
January 7, 2026
·
2 min read
·
Heather McKenzie
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
January 7, 2026
·
3 min read
·
Jennifer Smith-Parker
Weight Loss
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
January 6, 2026
·
3 min read
·
Annalee Armstrong
Immunology and inflammation
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease
January 6, 2026
·
2 min read
·
Tristan Manalac
